Compounds > trans-4-tert-butylcyclohexanol
Page last updated: 2024-12-05

trans-4-tert-butylcyclohexanol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

4-tert-butylcyclohexanol: a TRPV1 channel antagonist for treating sensitive skin; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID7391
CHEMBL ID1886723
SCHEMBL ID579573
SCHEMBL ID579272
SCHEMBL ID114150
SCHEMBL ID8365597
SCHEMBL ID7752973
MeSH IDM0557228

Synonyms (141)

Synonym
4-tert-butyl-cyclohexan-1-ol
AKOS015837824
AKOS015837822
cyclohexanol, 4-(1,1-dimethylethyl)-, trans-
cyclohexanol, 4-(1,1-dimethylethyl)-, cis-
cyclohexanol, 4-(1,1-dimethylethyl)-
cyclohexanol, 4-tert-butyl-, cis-
padaryl
brn 1902277
ai3-02503
einecs 202-676-4
nsc 404197
98-52-2
nsc-404197
4-tert-butylcyclohexanol
usaf do-20
nsc404197
cyclohexanol,1-dimethylethyl)-
cyclohexanol, 4-tert-butyl-
p-tert-butylcyclohexanol
wln: l6tj ax1 & 1 & 1 dq
NCGC00164215-01
hexahydro-p-tert-butylphenol
B0383
B1271 ,
21862-63-5
cis-4-tert-butylcyclohexanol
trans-4-tert-butylcyclohexanol
937-05-3
B1270 ,
4-tert-butylcyclohexan-1-ol
AKOS000120382
A844682
4-tert-butyl-1-cyclohexanol
A845870
NCGC00164215-02
cas-98-52-2
dtxcid606623
NCGC00256931-01
dtxsid5026623 ,
tox21_303090
NCGC00259065-01
tox21_201515
A815716
trans-4-(tert-butyl)cyclohexanol
unii-f5fz4y0umg
ec 700-127-8
4-tert-butylcyclohexanol, trans-
f5fz4y0umg ,
l5067jrj73 ,
4-tert-butylcyclohexanol, cis-
unii-l5067jrj73
cis-4-tert-butylcyclohexan-1-ol
einecs 213-321-8
FT-0687850
ec 202-676-4
unii-k0h1405s9c
1-06-00-00018 (beilstein handbook reference)
k0h1405s9c ,
FT-0619477
FT-0638157
BBL019113
4-(tert-butyl)cyclohexan-1-ol
4-(tert-butyl)cyclohexanol
4-cis-tert-butylcyclohexanol
cis-4-tert-butyl-1-cyclohexanol
SCHEMBL579573
SCHEMBL579272
4-t-butylcyclohexanol
cis-4-tert.-butyl-cyclohexanol
cis-4-(t-butyl)cyclohexanol
cis 4-tert-butylcyclohexanol
cis-4-tert-butyl cyclohexanol
cis 4-tert-butyl-cyclohexanol
cis-4-t-butylcyclohexanol
cis-4-tertbutylcyclohexanol
cis-4-(tert-butyl)cyclohexanol
cis-4-tert-butyl-cyclohexanol
SCHEMBL114150
trans-4-tert-butyl cyclohexanol
trans 4-tert-butyl-cyclohexanol
trans-4-t-butylcyclohexanol
trans-4-tert-butyl-cyclohexanol
cyclohexanol, 4-(1,1-dimethylethyl)-, trans
trans-1-tert-butylcyclohexan-4-ol
trans-4-tert-butylcyclohexanol [who-dd]
trans-p-tert-butylcyclohexanol
fema no. 4724
trans-4-tert-butyl-1-cyclohexanol
trans-4-tert-butylcyclohexyl alcohol
cyclohexanol, 4-tert-butyl-, trans-
SCHEMBL8365597
(e)-4-tert-butylcyclohexanol
4-tert-butylcyclohexanol, (z)-
4-tert-butylcyclohexanol,c&t
4-tert-butyl cyclohexanol
4-tert.-butyl-cyclohexanol
4-terbutyl-cyclohexanol
4-tert-butyl-cyclohexanol
p-tert-butyl cyclohexanol
4-t-butyl-1-cyclohexanol
SCHEMBL7752973
butylcyclohexanol; 95%
Q-200399
3-xylenediamine
CHEMBL1886723
STR03673
cyclohexanol,4-(1,1-dimethylethyl)-,cis-
F0001-2316
mfcd00064952
mfcd00070476
mfcd00001473
AS-60986
AS-60214
(1r,4r)-4-tert-butylcyclohexan-1-ol
(1s,4s)-4-tert-butylcyclohexan-1-ol
(1s,4s)-4-tert-butylcyclohexanol
cis-4-tert-butylcyclhexanol
(1r,4r)-4-tert-butylcyclohexanol
BCP30881
EN300-20213
STL199047
AMY3572
Q27277664
Q27282714
P20543
T71478
T70576
DTXSID50885182
DTXSID40883571
trans-4-(tert-butyl)cyclohexanol relative stereochemistry
A858538
A859665
WAA86263
SB83913
SB84138
CS-W010920
CS-0343022
CS-0343024
EN300-6735394
Z104477300
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency40.20830.007215.758889.3584AID1224835
AR proteinHomo sapiens (human)Potency0.34380.000221.22318,912.5098AID743042
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency47.12530.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency31.62280.000817.505159.3239AID588544
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency45.80040.001530.607315,848.9004AID1224841; AID1224848; AID1259401; AID1259403
estrogen nuclear receptor alphaHomo sapiens (human)Potency49.66200.000229.305416,493.5996AID743069
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.22000.001628.015177.1139AID1259385
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency27.30600.000323.4451159.6830AID743065
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)Potency1.12200.015823.527344.6684AID651778
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (50)

Processvia Protein(s)Taxonomy
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (23)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (87.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (62.50%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (37.50%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2-aminoethoxydiphenyl borate
2-aminoethoxydiphenyl borate: is a novel membrane-penetrable modulator and transient receptor potential channel blocker; structure in first source; do not confuse with 2-APB cpd. 2-aminoethoxydiphenylborane : An organoboron compound that is diphenylborane in which the borane hydrogen is replaced by a 2-aminoethoxy group.		4.3611organoboron compound;
primary amino compound		calcium channel blocker;
IP3 receptor antagonist;
potassium channel opener
nonivamide
nonivamide: has effect on sensory neurons. nonivamide : A capsaicinoid that is the carboxamide resulting from the formal condensation of the amino group of 4-hydroxy-3-methoxybenzylamine with the carboxy group of nonanoic acid. It is the active ingredient in many pepper sprays.		2.0810capsaicinoid;
phenols		lachrymator
triamcinolone acetonide
Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.		3.561111beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone		anti-allergic agent;
anti-inflammatory drug
cyclohexanol
Cyclohexanols: Monohydroxy derivatives of cyclohexanes that contain the general formula R-C6H11O. They have a camphorlike odor and are used in making soaps, insecticides, germicides, dry cleaning, and plasticizers.. cyclohexanols : An alcohol in which one or more hydroxy groups are attached to a cyclohexane skeleton.		7.3285cyclohexanols;
secondary alcohol		solvent
capsaicin
ALGRX-4975: an injectable capsaicin (TRPV1 receptor agonist) formulation for longlasting pain relief. capsaicinoid : A family of aromatic fatty amides produced as secondary metabolites by chilli peppers.		6.2343capsaicinoidnon-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker
capsazepine
capsazepine: modified capsaicin molecule; a capsaicin receptor antagonist. capsazepine : A benzazepine that is 2,3,4,5-tetrahydro-1H-2-benzazepine which is substituted by hydroxy groups at positions 7 and 8 and on the nitrogen atom by a 2-(p-chlorophenyl)ethylaminothiocarbonyl group. A synthetic analogue of capsaicin, it was the first reported capsaicin receptor antagonist.		2.0810benzazepine;
catechols;
monochlorobenzenes;
thioureas		capsaicin receptor antagonist
dinoprostone
prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.		3.5111prostaglandins Ehuman metabolite;
mouse metabolite;
oxytocic
licochalcone a
licochalcone A: has both anti-inflammatory and antineoplastic activities; structure given in first source; isolated from root of Glycyrrhiza inflata; RN given refers to (E)-isomer		542chalcones
ConditionIndicatedRelationship StrengthStudiesTrials
Dermatitis, Periocular
[description not available]		03.6411
Dermatitis, Perioral
A papular eruption of unknown etiology that progresses to residual papular erythema and scaling usually confined to the area of the mouth, and almost exclusively occurring in young women. It may also be localized or extend to involve the eyelids and adjacent glabella area of the forehead (periocular dermatitis). (Dorland, 28th ed)		03.6411
Acne Rosacea
[description not available]		02.5420
Dermatoses
[description not available]		04.821
Rosacea
A cutaneous disorder primarily of convexities of the central part of the FACE, such as FOREHEAD; CHEEK; NOSE; and CHIN. It is characterized by FLUSHING; ERYTHEMA; EDEMA; RHINOPHYMA; papules; and ocular symptoms. It may occur at any age but typically after age 30. There are various subtypes of rosacea: erythematotelangiectatic, papulopustular, phymatous, and ocular (National Rosacea Society's Expert Committee on the Classification and Staging of Rosacea, J Am Acad Dermatol 2002; 46:584-7).		02.5420
Skin Diseases
Diseases involving the DERMIS or EPIDERMIS.		04.821
Facial Dermatoses
Skin diseases involving the FACE.		05.1433
Ache
[description not available]		04.4822
Sensation Disorders
Disorders of the special senses (i.e., VISION; HEARING; TASTE; and SMELL) or somatosensory system (i.e., afferent components of the PERIPHERAL NERVOUS SYSTEM).		06.0133
Erythema
Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.		03.9221
Pain
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.		04.4822
Spider Veins
[description not available]		02.1310
Telangiectasis
Permanent dilation of preexisting blood vessels (CAPILLARIES; ARTERIOLES; VENULES) creating small focal red lesions, most commonly in the skin or mucous membranes. It is characterized by the prominence of skin blood vessels, such as vascular spiders.		02.1310